Compare · treatment

Autologous MSC
vs Allogeneic MSC.

Two main MSC sources, both NMPA-licenced at Chinese Class A facilities. Autologous (your own cells) avoids rejection but requires harvest and 7–14 day processing. Allogeneic (donor umbilical cord cells) is off-the-shelf with stronger immunomodulatory profile but requires careful matching.

Verdict

The bottom line.

Autologous for: orthopedic OA, post-injury, autoimmune in younger patients with good cell quality. Allogeneic for: GVHD, refractory autoimmune, severe systemic inflammation, urgent need without time for harvest, older patients with reduced cell yield.

Side-by-side

Autologous MSC vs Allogeneic MSC, by the numbers.

Autologous MSC
Allogeneic MSC
Cell source
Your own (bone marrow, adipose, banked cord)
Donor (umbilical cord most common)
Rejection riskAutologous MSC
None (autologous)
Low (MSCs are immunoprivileged)
Processing timeAllogeneic MSC
7–14 days after harvest
Off-the-shelf (no delay)
Harvest requirementAllogeneic MSC
Yes (iliac crest aspiration or mini-liposuction)
No
Cell potency in older patientsAllogeneic MSC
Reduced after age 50–60
Consistent (young donor)
Immunomodulatory effectAllogeneic MSC
Moderate
Stronger (UC-MSC)
Standardised dosingAllogeneic MSC
Variable per harvest yield
Standardised
Best for OA / post-injuryAutologous MSC
Strong indication
Acceptable alternative
Best for GVHDAllogeneic MSC
Not standard
NMPA-approved (Ruibosheng)
Best for refractory autoimmuneAllogeneic MSC
Limited evidence
Stronger evidence
All-in cost (China)Autologous MSC
$8,400–$24,000
$10,000–$28,000
Total trip daysAllogeneic MSC
21–28 (harvest + processing + infusion)
10–14 (infusion only)

Verdict markers (↑) indicate where the listed option has a clear advantage based on aggregate evidence and pricing as of 2024–2025. Individual cases vary — request a personalized assessment for your specific situation.

FAQ

Autologous MSC vs Allogeneic MSC, answered.

Which is better — autologous or allogeneic MSC?
Neither is universally better. Autologous is preferred for orthopedic OA and younger patients with good cell quality. Allogeneic is preferred for GVHD (NMPA-approved indication), urgent or systemic inflammatory conditions, and older patients where autologous yield is reduced. Your physician will recommend based on your indication, age, and timeline.
Is autologous always safer than allogeneic?
Marginally. Both have excellent safety profiles at NMPA-licensed Class A facilities. Autologous eliminates donor-screening dependence but requires invasive harvest. Allogeneic from screened umbilical cord tissue has serious adverse event rates <1% in published trials. Practical safety difference is small at top centres.
How does processing time differ?
Autologous: harvest day 1, processing 7–14 days, infusion. Total on-site stay 21–28 days. Allogeneic: pre-screened banked cells, infusion within 1–3 days of arrival. Total on-site stay 10–14 days. For patients with limited time, allogeneic is significantly more convenient.

Need a personalized
recommendation?

The verdict above is general. Send your case and we’ll return a personalized recommendation — destination, hospital, treatment plan and itemized quote — in 5 business days.